Search for content and authors
 

Preparation and physicochemical properties of crystalline forms and amorphous pemetrexed disodium

Olga M. Michalak ,  Kamil Jatczak ,  Anna B. Witkowska ,  Marta Łaszcz ,  Wiesław Pucko ,  Iwona Bujak ,  Aleksandra Groman 

Pharmaceutical Research Institute, Rydygiera 8, Warsaw 01-793, Poland

Abstract
The commercial product pemetrexed disodium, a known anticancer drug, is used for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC).

Two hydrate forms heptahydrate and hemipentahydrate as well as amorphous pemetrexed disodium are currently well established in the literature. The heptahydrate form is used in marketed products.
We have developed processes for preparation of hemipentahydrate form and amorphous pemetrexed disodium. These developed processes are in compliance with the purity requirements for an active substance used in a medicinal product.
Two approaches for the preparation of pemetrexed disodium were used. In the first approach, hydrolysis of diethyl ester in aqueous sodium hydroxide solution led to hemipentahydrate form. In the second approach, deprotonation of pemetrexed diacid in the presence of sodium methoxide in the anhydrous conditions gave amorphous pemetrexed disodium.

The physicochemical characterization of crystalline forms and amorphous pemetrexed disodium as well as  starting materials and process-related impurities was accomplished using various analytical methods (IR, NMR, XRPD, DSC, TG).

 

Legal notice
  • Legal notice:

    Copyright (c) Pielaszek Research, all rights reserved.
    The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
    In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/31067 must be provided.

 

Related papers
  1. Synthesis of 1’-(saccharide)substituted 28-O-(1’H-[1’,2’,3’]triazolyl-4’-methyl) derivatives of protoescigenin
  2. Determination of organic volatile impurities in Nepafenac by GC method
  3. Improved manufacturing process of bosentan monohydrate.
  4. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
  5. Characterization of dutasteride polymorphic forms
  6. Comparison of ultraviolet detection and charged aerosol detection methods for liquid-chromatographic determination of protoescigenin
  7. N-terminal amidinated derivatives of the cyclic 1,4-ureido-deltorphin analogues: the synthesis and  receptor binding studies
  8. Selective protection of protoescigenin as the key step in synthesis of escin analogs
  9. Development and validation of GCMS method for the control of ethyl and izopropyl methanesulphonates in pharmaceutical substance in a form of mesilate
  10. Synthesis of potential impurities of loteprednol etabonate and methods for chemical purity determination
  11. New cyclic dermorphin analogues containing a carbonyl bridge
  12. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
  13. Physicochemical characterization of sunitinib and its impurities
  14. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism
  15. Preparation of protoaescigenin from escin.
  16. Validation of a HPLC method for LI-S analysis
  17. Structural characterization of PX-S
  18. Method development and validation of an analytical procedure - control of residual 2-iodopropane in Latanoprost
  19. Quantification of active substance in drug by Rietveld analysis
  20. Validation of an analytical procedure – control of residual 8 solvents in a pharmaceutical substance
  21. A novel synthesis of antineoplastic drugs docetaxel and paclitaxel
  22. High-yielded method of synthesis of voriconazole.
  23. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
  24. Optimization of AR-3 synthesis
  25. VALIDATION OF AN ANALYTICAL PROCEDURE - CONTROL OF RESIDUAL ETHANOL, 2-PROPANOL AND ETHYL ACETATE IN PHARMACEUTICAL SUBSTANCE
  26. VALIDATION OF AN ANALYTICAL PROCEDURE - CONTROL OF RESIDUAL 9 SOLVENTS IN PHARMACEUTICAL SUBSTANCE
  27. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  28. THE VALIDATION OF ANALYTICAL METHODS OF A PHARMACEUTICAL ACTIVE SUBSTANCE PRODUCED IN SMALL SCALE PLANT (SSP). THE EXAMPLE OF PIOGLITAZONE HYDROCHLORIDE.
  29. GC METHOD FOR QUANTITATIVE DETER- MINATION OF RESIDUAL 2-(2-CHLORO- ETOXY)ETHANOL (CEE) AND N-METHYL- 2-PYRROLIDINONE (NMP) IN PHARMACEU- TICAL ACTIVE SUBSTANCE
  30. SYNTHESIS OF PIOGLITAZONE HYDROCHLORIDE OF PHARMACEUTICAL PURITY AT SMALL PLANT SCALE
  31. SYNTHESIS OF 25- HYDROXYVITAMIN D3 - CALCIFEDIOL FROM VITAMIN D2

Presentation: Poster at IX Multidyscyplinarna Konferencja Nauki o Leku, by Olga M. Michalak
See On-line Journal of IX Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2014-03-13 14:55
Revised:   2014-05-02 13:04